Dezapelisib - Incyte Corporation

Drug Profile

Dezapelisib - Incyte Corporation

Alternative Names: INCB-40093; INCB040093

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics; Purines; Pyrimidinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 08 May 2017 Incyte corporation terminates a phase II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675) due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma
  • 01 Jan 2017 Incyte corporation completes a phase-II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675)
  • 12 Dec 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top